RESUMO
OBJECTIVES: Achieving complete response (CR) has been linked to improved progression-free (PFS) and overall (OS) survival in myeloma. A meta-analysis was conducted to investigate whether this holds true in the era of novel agents (bortezomib, lenalidomide, thalidomide). METHODS: A total of 24 studies in newly diagnosed patients undergoing autologous stem cell transplantation (ASCT) that reported associations between responses and long-term outcomes (PFS/OS rates post-ASCT by response, or hazard ratios with 95% confidence intervals from Cox models) were identified and analyzed. RESULTS: Achievement of CR vs. Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
, Mieloma Múltiplo/tratamento farmacológico
, Mieloma Múltiplo/mortalidade
, Transplante de Células-Tronco Hematopoéticas
, Humanos
, Estimativa de Kaplan-Meier
, Mieloma Múltiplo/terapia
, Razão de Chances
, Modelos de Riscos Proporcionais
, Indução de Remissão
, Transplante Autólogo
, Resultado do Tratamento